Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
23 results
D1.270 - Irish Infant Allergy and Nutrition: A Content Analysis of Public-Facing Online Guidance
D1.273 - Burden of food allergy on daily life and emotions in children and parents: Insights from the IPAA French Cohort
D1.274 - Evaluating adherence to and effectiveness of food allergy advice in parents of infants under 6 months old suffering from atopic dermatitis
D1.264 - A Case of Chronic Food Protein-Induced Enterocolitis Syndrome triggered by Egg Yolk via Breast Milk
D1.265 - Predicting Milk Ladder Outcomes for Management of IgE-Mediated Cow’s Milk Protein Allergy: Feature Selection Using Machine Learning Methods
D1.266 - Phenotypes of IgE-mediated Cow’s Milk Protein Allergy in an Irish Cohort Using Latent Class Analysis
D1.267 - Clinical Features and Dairy Triggers for Cow’s Milk Allergy among 342 Chinese Children in a University-affiliated Allergy Clinic in Hong Kong
D1.268 - Advancing Paediatric Egg Allergy Management via Telemedicine: Outcomes of Remote Egg Ladder Support
D1.271 - Parental Vaccine Hesitancy And Immunization Practices In Children With Food Allergy
D1.272 - Improving Culinary Medicine and Food Allergy Knowledge Through a STEM-Integrated Medical-Student-Led Cooking Program for Youth in New Orleans
D1.275 - Pollen-Food Allergy Syndrome among Final-Year Primary School Students in the City of Olsztyn and Olsztyn County, Poland: A Questionnaire-Based Cross-Sectional Study
D1.277 - Selective goat’s and sheep’s milk anaphylaxis: Advocacy for mandatory food labeling of milk origins
D3.418 - A Phase 1b Study of Lesigercept, a Long-acting High-affinity IgETrap-Fc Fusion Protein: Safety, Tolerability, PK, and PD in Atopic Healthy and Allergic Subjects
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.421 - Real-world Effectiveness and Safety of Lanadelumab Treatment in Patients With Hereditary Angioedema: The 12-Month Interim Analysis of a Polish, Prospective, Multicenter, Observational Study (CHOPIN)
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.423 - Lanadelumab treatment is effective and safe in patients with Factor XII associated cold-induced autoinflammatory syndrome: results from an open-label proof-of-concept study
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download